• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by SAB Biotherapeutics Inc.

    4/3/25 5:15:36 PM ET
    $SABS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $SABS alert in real time by email
    S-8 1 sabs_s-8_fy25apr.htm S-8 S-8

     


    As filed with the Securities and Exchange Commission on April 3, 2025

    Registration No. 333-

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM S-8
    REGISTRATION STATEMENT
    Under
    The Securities Act of 1933

    SAB Biotherapeutics, Inc.
    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware

    85-3899721

    (State or other jurisdiction of
    incorporation or organization)

    (I.R.S. Employer
    Identification No.)

     

     

     

    777 W 41st St., Suite 401

    Miami Beach, Florida

    33140

    (Address of Principal Executive Offices)

    (Zip Code)


    SAB Biotherapeutics, Inc. 2021 Omnibus Equity Incentive Plan,

    As Amended
    (Full title of the plans)

    Samuel J. Reich
    Chief Executive Officer
    SAB Biotherapeutics, Inc.
    777 W 41
    st St., Suite 401
    Miami Beach, Florida 33140
    (Name and address of agent for service)

    (305)-845-2813
    (Telephone number, including area code, of agent for service)

    Copies to:

     

    Ilan Katz, Esq.

    Brian Lee, Esq.

    Dentons US LLP

    1221 Avenue of the Americas

    New York, New York 10020

    Tel: (212) 768-6700

     

     


     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

     

     

    Large accelerated filer ☐

    Accelerated filer ☐

    Non-accelerated filer ☒

    Smaller reporting company ☒

    Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     


     

    EXPLANATORY NOTE

    SAB Biotherapeutics, Inc., a Delaware corporation (the “Registrant”) is filing this Registration Statement on Form S-8 (the “Registration Statement”) for the purpose of registering an additional 2,252,466 shares of its common stock, par value $0.0001 per share (the “Common Stock”), issuable to eligible persons under the SAB Biotherapeutics, Inc. 2021 Omnibus Equity Incentive Plan (as amended, the “2021 Plan”), which shares are in addition to the shares registered on the Registrant’s registration statement on Form S-8 filed with the Securities and Exchange Commission (the “Commission”) on February 1, 2022 (File No. 333-262452), the registration statement on Form S-8 filed with the Commission on February 23, 2024 (File No. 333-277314), and the registration statement on Form S-8 filed with the Commission on August 12, 2024 (File No. 333-281499) (together, the “Prior Registration Statements”).

    This Registration Statement relates to securities of the same class as that to which the Prior Registration Statements relate, and is submitted in accordance with General Instruction E (“General Instruction E”) to Form S-8 under the Securities Act of 1933, as amended (the “Securities Act”), regarding Registration of Additional Securities. Pursuant to General Instruction E, the contents of the Prior Registration Statements, to the extent relating to the registration of Common Stock issuable under the 2021 Plan, are incorporated herein by reference and made part of this Registration Statement, except to the extent supplemented, amended and superseded by the information set forth herein.

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    Item 3. Incorporation of Documents by Reference

    The following documents filed with the Commission by the Registrant pursuant to the Securities Act and the Securities Exchange Act of 1934, as amended (the “Exchange Act”), are hereby incorporated by reference into this Registration Statement:

    (a)
    the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024 (as filed with the Commission on March 31, 2025);
    (b)
    the Registrant’s Current Reports on Form 8-K filed with the Commission on January 28, 2025 and February 5, 2025; and
    (c)
    the description of the Registrant’s Common Stock contained in the registrant’s registration statement on Form 8-A , filed by the registrant with the Commission under Section 12(b) of the Exchange Act on January 8, 2021, including any amendments or reports filed for the purpose of updating such description.

    All documents that the Registrant subsequently files pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act prior to the filing of a post-effective amendment to this Registration Statement that indicates that all of the shares of Common Stock offered have been sold or that deregisters all of such shares then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of the filing of such documents.

    Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

    Under no circumstances will any information filed under current items 2.02 or 7.01 of Form 8-K be deemed incorporated herein by reference unless such Form 8-K expressly provides to the contrary.

    3


     

    Item 8. Exhibits.

    EXHIBIT INDEX

     

     

     

    Exhibit
    No.

    Description

    4.1

    Amended and Restated Certificate of Incorporation of the registrant (incorporated by reference to Exhibit 3.1 to the current report on Form 8-K, filed with the Commission on October 28, 2021).

    4.2

    Amended and Restated Bylaws of the registrant (incorporated by reference to Exhibit 3.2 to the current report on Form 8-K filed with the Commission on October 28, 2021).

    4.3

    Specimen Common Stock Certificate of the Company (incorporated by reference to Exhibit 4.2 to the Registration Statement on Form S-1 January 4, 2021).

    4.4

    Certificate of Designation of Preferences, Rights and Limitations of the Series A Convertible Voting Preferred Stock (incorporated by reference to Exhibit 3.1 to the current report on Form 8-K, filed with the Commission on October 2, 2023).

    4.5

    Certificate of Amendment to the Certificate of Incorporation, as amended and restated, dated January 2, 2024 (incorporated by reference to Exhibit 3.1 to the current report on Form 8-K, filed with the Commission on January 3, 2024).

    5.1*

    Opinion of Dentons US LLP.

    23.1*

    Consent of EisnerAmper LLP, independent registered public accounting firm.

    23.2*

    Consent of Dentons US LLP (included in Exhibit 5.1).

    24.1*

    Power of Attorney (included on signature page of this registration statement).

    99.1

     

    SAB Biotherapeutics, Inc. 2021 Omnibus Equity Incentive Plan, as amended. (incorporated by reference to Exhibit 10.2 to the Quarterly Report on Form 10-Q filed with the Commission on August 8, 2024).

    107*

    Filing Fee Table.

    *Filed herewith.

     

    4


     

    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Miami Beach, Florida on April 3, 2025.

    SAB BIOTHERAPEUTICS, INC.

    By:

    /s/ Samuel J. Reich

    Name:

    Samuel J. Reich

    Title:

    Chief Executive Officer

    POWER OF ATTORNEY AND SIGNATURES

    KNOW ALL PERSONS BY THESE PRESENTS, that each individual whose signature appears below hereby constitutes and appoints each of Samuel J. Reich and Lucy To as such person’s true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for such person in such person’s name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement on Form S-8, and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Commission granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that any said attorney-in-fact and agent, or any substitute or substitutes of any of them, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following person in the capacities and on the date indicated below.

    Signature

     

    Title

     

    Date

     

     

     

     

     

    /s/ Samuel J. Reich

     

    Chair and Chief Executive Officer

     

    April 3, 2025

    Samuel J. Reich

     

    (Principal Executive Officer)

     

     

     

     

     

     

     

    /s/ Lucy To

     

    Chief Financial Officer

     

    April 3, 2025

    Lucy To

     

    (Principal Financial Officer and Principal Accounting Officer)

     

     

     

     

     

     

     

    /s/ Eddie J. Sullivan, PhD

     

    President and Director

     

    April 3, 2025

    Eddie J. Sullivan, PhD

     

     

     

     

     

     

     

     

     

    /s/ Katie Ellias

     

    Director

     

    April 3, 2025

    Katie Ellias

     

     

     

     

     

     

     

     

     

    /s/ Christine Hamilton, MBA

     

    Director

     

    April 3, 2025

    Christine Hamilton, MBA

     

     

     

     

     

     

     

     

     

    /s/ Scott Giberson, RPh, MPH, D.Sc.

     

    Director

     

    April 3, 2025

    Scott Giberson, RPh, MPH, D.Sc.

     

     

     

     

     

    /s/ David Link, MBA

     

    Director

     

    April 3, 2025

     


     

    David Link, MBA

     

     

     

     

     

     

     

     

     

    /s/ Erick Lucera

     

    Director

     

    April 3, 2025

    Erick Lucera

     

     

     

     

     

    /s/ Andrew Moin

    Director

     

    April 3, 2025

    Andrew Moin

     

     

    /s/ William Polvino, MD

    Director

     

    April 3, 2025

    William Polvino, MD

     

     

    /s/ Jay Skyler, MD

    Director

     

    April 3, 2025

    Jay Skyler, MD

     

     

     

     

     

     

    /s/ Jeffrey G. Spragens

    Director

     

    April 3, 2025

    Jeffrey G. Spragens

     

     

     

     


    Get the next $SABS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SABS

    DatePrice TargetRatingAnalyst
    10/9/2024$11.00Buy
    Craig Hallum
    8/28/2024$12.00Outperform
    Oppenheimer
    11/5/2021$17.00Buy
    Chardan Capital Markets
    11/2/2021$23.00Outperform
    Robert W. Baird
    11/2/2021$23.00Outperform
    Baird
    More analyst ratings

    $SABS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • SAB BIO Announces Q1 2025 Financial Results and Provides Company Updates

      MIAMI, May 09, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS), ("SAB BIO" or the "Company"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced financial results for the quarter ending March 31, 2025, and reported on recent developments. Samuel J. Reich, Chairman and CEO of SAB BIO, stated, "We have made strong progress this quarter on our corporate strategy and mission to deliver a transformational therapy that can halt or delay the progression of type 1 diabetes. Based on our recent positive Phase 1 topline data for

      5/9/25 9:00:40 AM ET
      $SABS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SAB BIO Reports Full Year 2024 Operating and Financial Results

      MIAMI, March 31, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS), ("SAB BIO" or the "Company"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced financial results for the fourth quarter of 2024 in addition to its full year financial results for the fiscal year ended December 31, 2024, and reported on recent accomplishments and anticipated milestones. Samuel J. Reich, Chairman and CEO of SAB BIO stated, "Our recent announcement of positive topline data for SAB-142, further strengthens our belief that SAB-142 has the pote

      3/31/25 7:32:00 AM ET
      $SABS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SAB BIO to Participate in Upcoming Investor Conferences

      MIAMI, Jan. 31, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS), ("SAB BIO" or the "Company"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing SAB-142, a human anti-thymocyte immunoglobulin (hIgG) that potentially delays the onset or progression of type 1 diabetes (T1D), today announced that members of its management team will participate in the following investor conferences: Event: Guggenheim SMID Cap Biotech ConferenceDate: February 6, 2025Fireside Chat: 2:00 – 2:25pm ETWebcast Link: https://wsw.com/webcast/guggen2/sabs/1999239 Event: Oppenheimer 35th Annual Healthcare Life Sciences ConferenceDate: February 12, 2025Company Presenta

      1/31/25 7:00:00 AM ET
      $SABS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SABS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by SAB Biotherapeutics Inc. (Amendment)

      SC 13G/A - SAB Biotherapeutics, Inc. (0001833214) (Subject)

      2/14/24 4:05:33 PM ET
      $SABS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by SAB Biotherapeutics Inc.

      SC 13G - SAB Biotherapeutics, Inc. (0001833214) (Subject)

      2/14/24 7:02:03 AM ET
      $SABS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by SAB Biotherapeutics Inc. (Amendment)

      SC 13G/A - SAB Biotherapeutics, Inc. (0001833214) (Subject)

      2/14/24 6:28:12 AM ET
      $SABS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SABS
    SEC Filings

    See more
    • SEC Form 10-Q filed by SAB Biotherapeutics Inc.

      10-Q - SAB Biotherapeutics, Inc. (0001833214) (Filer)

      5/9/25 8:42:30 AM ET
      $SABS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-8 filed by SAB Biotherapeutics Inc.

      S-8 - SAB Biotherapeutics, Inc. (0001833214) (Filer)

      4/3/25 5:15:36 PM ET
      $SABS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by SAB Biotherapeutics Inc.

      SCHEDULE 13G/A - SAB Biotherapeutics, Inc. (0001833214) (Subject)

      2/14/25 9:00:04 AM ET
      $SABS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SABS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHIEF MEDICAL OFFICER Kropotova Alexandra covered exercise/tax liability with 1,179 shares, decreasing direct ownership by 2% to 47,249 units (SEC Form 4)

      4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)

      4/1/25 4:19:49 PM ET
      $SABS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • CHIEF MEDICAL OFFICER Kropotova Alexandra covered exercise/tax liability with 9,072 shares, decreasing direct ownership by 16% to 48,428 units (SEC Form 4)

      4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)

      12/31/24 5:49:34 PM ET
      $SABS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Ellias Helen K.

      4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)

      11/5/24 4:41:10 PM ET
      $SABS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SABS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Sullivan Eddie Joe bought $1,531 worth of shares (1,740 units at $0.88), increasing direct ownership by 0.03% to 5,232,304 units (SEC Form 4)

      4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)

      12/8/23 8:00:05 AM ET
      $SABS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • King Michael bought $4,500 worth of shares (5,000 units at $0.90) (SEC Form 4)

      4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)

      11/30/23 5:00:07 PM ET
      $SABS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Reich Samuel J bought $9,842 worth of shares (11,000 units at $0.89), increasing direct ownership by 5% to 219,001 units (SEC Form 4)

      4 - SAB Biotherapeutics, Inc. (0001833214) (Issuer)

      11/30/23 8:00:04 AM ET
      $SABS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SABS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Craig Hallum initiated coverage on SAB BIO with a new price target

      Craig Hallum initiated coverage of SAB BIO with a rating of Buy and set a new price target of $11.00

      10/9/24 8:27:55 AM ET
      $SABS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Oppenheimer initiated coverage on SAB BIO with a new price target

      Oppenheimer initiated coverage of SAB BIO with a rating of Outperform and set a new price target of $12.00

      8/28/24 7:53:59 AM ET
      $SABS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chardan Capital Markets initiated coverage on SAB Biotherapeutics with a new price target

      Chardan Capital Markets initiated coverage of SAB Biotherapeutics with a rating of Buy and set a new price target of $17.00

      11/5/21 8:44:57 AM ET
      $SABS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SABS
    Leadership Updates

    Live Leadership Updates

    See more
    • SAB BIO Reports Full Year 2024 Operating and Financial Results

      MIAMI, March 31, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS), ("SAB BIO" or the "Company"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced financial results for the fourth quarter of 2024 in addition to its full year financial results for the fiscal year ended December 31, 2024, and reported on recent accomplishments and anticipated milestones. Samuel J. Reich, Chairman and CEO of SAB BIO stated, "Our recent announcement of positive topline data for SAB-142, further strengthens our belief that SAB-142 has the pote

      3/31/25 7:32:00 AM ET
      $SABS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SAB BIO Announces Second Quarter 2024 Financial Results and Provides Company Updates

      FDA provided clearance to SAB's IND Appointed Lucy To as Chief Financial Officer Announced founding of a new Clinical Advisory Board MIAMI, Aug. 08, 2024 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS), ("SAB" or the "Company"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today reported financial results for the second quarter ended June 30, 2024, and provided a company update. "We've had a strong quarter as we drive closer to our upcoming SAB-142 milestones. We continue to see an urgent need for transformative therapies in this spa

      8/8/24 5:51:04 PM ET
      $SABS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SAB BIO Appoints Lucy To as Chief Financial Officer

      MIAMI, July 31, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), ("SAB" or the "Company"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced that Lucy To has been named Chief Financial Officer effective August 12, 2024. Ms. To brings over 18 years of investment banking and strategic operational expertise to SAB and will lead corporate finance, corporate strategy and approach to broader strategic business relationships at the company. "Lucy's proven track record and experience will prove invaluable t

      7/31/24 7:30:00 AM ET
      $SABS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SABS
    Financials

    Live finance-specific insights

    See more
    • SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142

      SAB-142 was generally well-tolerated among healthy volunteers; data from Phase 1 trial confirms SAB-142 does not cause serum sickness or anti-drug antibodies at target dose Study results support that SAB-142 is well-positioned for re-dosing in outpatient setting for type 1 diabetesResults will be presented in an R&D webinar event today at 8:00 am ET; registration details below MIAMI, Jan. 28, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS), ("SAB BIO" or the "Company"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today an

      1/28/25 7:00:00 AM ET
      $SABS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SAB BIO Announces R&D Webinar Event to Review Phase 1 Topline Results for SAB-142, a Disease-Modifying T1D Therapy

      MIAMI, Jan. 23, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS), ("SAB" or the "Company"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), announced today that the Company will host a Research and Development webinar on January 28, 2025 to discuss the topline data for Phase 1 clinical trial for its lead candidate, SAB-142. The webinar will feature presentations from SAB BIO's management team and T1D Key Opinion Leader (KOL) Michael Haller, MD, the division chief of the Pediatric Endocrinology Division at the University of Florida and S

      1/23/25 7:00:00 AM ET
      $SABS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results

      Sioux Falls, SD , March 29, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results March 29, 2024 SAB-142 Phase 1 trial on track for data release during 2024 Completed financing for up to $110 million with leading life science investors Cash and equivalents of $56.6 million as of December 31, 2023 Company expects its cash and equivalents, with exercise of Tranche B warrants, will fund operations into 2026 Sioux Falls, SD March 29, 2024 (GlobeNewswire)—SAB Biotherapeutics, Inc. (NASDAQ:SABS), ("SAB" or "the company"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immun

      3/29/24 7:15:00 AM ET
      $SABS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care